Table 4.
Significant prognostic factors and score for each factor
| Prognostic factor | Regression coefficient | Score | |
|---|---|---|---|
| Primary site | |||
| Slow growth | Hormone-dependent breast and prostate cancer, thyroid cancer, multiple myeloma, and malignant lymphoma | 0 | |
| Moderategrowth | Lung cancer treated with molecularly targeted drugs, hormone-independent breast and prostate cancer, renal cell carcinoma, endometrial and ovarian cancer, sarcoma, and others | 0.99 | 2 |
| Rapid growth | Lung cancer without molecularly targeted drugs, colorectal cancer, gastric cancer, pancreatic cancer, head and neck cancer, esophageal cancer, other urological cancers, melanoma, hepatocellular carcinoma, gall bladder cancer, cervical cancer, and cancers of unknown origin | 1.70 | 3 |
| Visceral metastasis | Nodular visceral or cerebral metastasis | 0.65 | 1 |
| Disseminated metastasis1 | 1.11 | 2 | |
| Laboratory data | Abnormal2 | 0.64 | 1 |
| Critical3 | 1.04 | 2 | |
| ECOG PS | 3 or 4 | 0.73 | 1 |
| Previous chemotherapy | 0.32 | 1 | |
| Multiple skeletal metastases | 0.43 | 1 | |
| Total | 10 | ||
1
Disseminated metastasis: Pleural, peritoneal, or leptomeningeal dissemination.
2
Abnormal: CRP ≥ 0.4 mg/dL, LDH ≥ 250 IU/L, or serum albumin <3.7 g/dL.
3
Critical: platelet <100,000/μL, serum calcium ≥10.3 mg/dL, or total bilirubin ≥1.4.